Highlights of Ophthalmology

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 41 , ISSUE 3ESP ( Jun-2013, 2013 ) > List of Articles


Tolerancia y Efectividad de los Análogos de Prostaglandinas en Pacientes Glaucomatosos

Jose Francisco Ortega-Santana

Citation Information : Ortega-Santana JF. Tolerancia y Efectividad de los Análogos de Prostaglandinas en Pacientes Glaucomatosos. 2013; 41 (3ESP):22-26.

DOI: 10.5005/hos-10101-41306

Published Online: 25-03-2013

Copyright Statement:  Copyright © 2013; Jaypee Brothers Medical Publishers (P) Ltd.


PDF Share
  1. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
  2. Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56.
  3. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. 1998 Oct;126(4):498-505.
  4. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005 Jul;112(7):1177- 85.
  5. Lee AJ, McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 2010 Jul 30;4:741-64.
  6. Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand. 2007 Dec;85(8):838-43. Epub 2007 Aug 2.
  7. Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized, doublemasked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma. 2003 Dec;12(6):463-5.
  8. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S77-89.
  9. Goldberg I, Cunha-Vaz J, Jakobsen JE, Nordmann JP, Trost E, Sullivan EK; International Travoprost Study Group. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001 Oct;10(5):414-22.
  10. Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL; Bimatoprost Study Group. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol. 2008 Oct;92(10):1387-92. Epub 2008 Jul 11.
  11. O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomized study. Ireland Latanoprost Study Group. Br J Ophthalmol. 2000 Jun;84(6):579-82.
  12. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2566-73.
  13. Fung AT, Reid SE, Jones MP, Healey PR, McCluskey PJ, Craig JC. Meta-analysis of randomized controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br J Ophthalmol. 2007 Jan;91(1):62-8. Epub 2006 Sep 6.
  14. Camras CB, Sheu WP; United States Latanoprost- Brimonidine Study Group. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma. 2005 Apr;14(2):161-7.
  15. Petounis A, Mylopoulos N, Kandarakis A, Andreanos D, Dimitrakoulias N. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece. J Glaucoma. 2001 Aug;10(4):316-24.
  16. Toris CB, Zhan GL, Zhao J, Camras CB, Yablonski ME. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol. 2001 Jun;131(6):722-8.
  17. Cheng JW, Xi GL, Wei RL, Cai JP, Li Y. Efficacy and tolerability of latanoprost compared to dorzolamide combined with timolol in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized, controlled trials. J Ocul Pharmacol Ther. 2009 Feb;25(1):55-64.
  18. Coleman AL, Lerner F, Bernstein P, Whitcup SM. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology. 2003 Dec;110(12):2362-8.
  19. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, maskedevaluator multicenter study. Am J Ophthalmol. 2003 May;135(5):688-703.
  20. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a metaanalysis of randomized controlled clinical trials. J Glaucoma. 2008 Dec;17(8):667-73.
  21. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001 Oct;132(4):472-84.
  22. Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y; Bimatoprost-Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006 Nov;90(11):1370-3. Epub 2006 Jul 6.
  23. Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006 Feb;113(2):239-46.
  24. Kammer JA, Katzman B, Ackerman SL, Hollander DA. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomized, maskedevaluator, multicentre study. Br J Ophthalmol. 2010 Jan;94(1):74-9. Epub 2009 Sep 1.
  25. Higginbotham EJ, Feldman R, Stiles M, Dubiner H; Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002 Jul;120(7):915-22.
  26. Barnebey HS, Orengo-Nania S, Flowers BE, Samples J, Mallick S, Landry TA, Bergamini MV. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005 Jul;140(1):1-7.
  27. Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I; Ganfort Investigators Group II. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008 Apr-May;17(3):211-6.
  28. Morgan PV, Proniuk S, Blanchard J, Noecker RJ. Effect of temperature and light on the stability of latanoprost and its clinical relevance. J Glaucoma. 2001 Oct;10(5):401-5.
  29. Johnson TV, Gupta PK, Vudathala DK, Blair IA, Tanna AP. Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use. J Ocul Pharmacol Ther. 2011 Feb;27(1):51-9. Epub 2010 Nov 30.
  30. Okeke CO, Quigley HA, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Friedman DS. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009 Feb;116(2):191-9. Epub 2008 Dec 12.
  31. Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008 Aug;43(4):454-61.
  32. Friedman DS, Okeke CO, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Quigley HA. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology. 2009 Jun;116(6):1097-105. Epub 2009 Apr 19.
  33. Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009 Mar;18(3):238-43.
  34. Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009 Apr;25(2):145-52.
  35. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol. 2004 Jan;137(1 Suppl):S3-12.
  36. Honrubia F, García-Sánchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomized clinical trials. Br J Ophthalmol. 2009 Mar;93(3):316-21. Epub 2008 Nov 19.
  37. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S105-15.
  38. Kobayashi H, Kobayashi K. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect. J Glaucoma. 2011 Jan;20(1):3-6.
  39. Schwartz GF, Tan J, Kotak S. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs. Ocul Pharmacol Ther. 2009 Dec;25(6):555-61.
  40. Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291-5. Epub 2009 Jun 2.
  41. Katz G, Springs CL, Craven ER, Montecchi-Palmer M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAKpreserved latanoprost or BAK-free travoprost. Clin Ophthalmol. 2010 Nov 3;4:1253-61.
  42. Cracknell KP, Grierson I. Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects. Exp Eye Res. 2009 Apr;88(4):786-91. Epub 2008 Oct 2.
  43. Teus MA, Arranz-Márquez E, Lucea-Suescun P. Incidence of iris color change in latanoprost treated eyes. Br J Ophthalmol. 2002 Oct;86(10):1085-8.
  44. Albert DM, Gangnon RE, Grossniklaus HE, Green WR, Darjatmoko S, Kulkarni AD. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides. Arch Ophthalmol. 2008 May;126(5):626-31.
  45. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997 Oct;124(4):544-7.
  46. Sharpe ED, Reynolds AC, Skuta GL, Jenkins JN, Stewart WC. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res. 2007 Dec;32(12):1037-43.
  47. Fechtner RD, Khouri AS, Zimmerman TJ, Bullock J, Feldman R, Kulkarni P, Michael AJ, Realini T, Warwar R. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998 Jul;126(1):37-41.
  48. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999 May;127(5):602-4.
  49. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol. 2002 Mar;133(3):401-3.
  50. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998 Feb;105(2):263-8.
  51. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol. 2000 Apr;11(2):94- 100
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.